Acumen Pharmaceuticals (ABOS) Receivables - Accured (2023 - 2024)
Acumen Pharmaceuticals (ABOS) posted Receivables - Accured of $53000.0 for Q4 2024, down 76.44% sequentially from $225000.0 in Q4 2023, and down 76.44% YoY from $225000.0 in Q1 2024.
Acumen Pharmaceuticals (ABOS) Receivables - Accured (2023 - 2024) Analysis & Trends
Acumen Pharmaceuticals has reported Receivables - Accured for 2 years, with the latest figure at $53000.0 in Q4 2024.
- Quarterly Receivables - Accured fell 76.44% year-over-year to $53000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $53000.0 (down 76.44% YoY) and the FY2024 annual result came in at $53000.0, down 76.44% from the prior year.
- Receivables - Accured retreated to $53000.0 in Q4 2024 per ABOS's latest filing, from $225000.0 in the prior quarter.
- Over five years, Receivables - Accured peaked at $225000.0 in Q4 2023 and troughed at $53000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2023 | 225,000.00 |
| Dec 31, 2023 | 225,000.00 |